<DOC>
	<DOCNO>NCT02761252</DOCNO>
	<brief_summary>The purpose study compare concomitant administration Montelukast Bilastine Montelukast Bilastine monotherapies patient SARC asthma</brief_summary>
	<brief_title>Efficacy Co-administration Bilastine Montelukast Patients With SARC Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>INCLUSION CRITERIA 1 . Patients age 18 year old ; 2 . Patients least 2 year history SARC prior study mild moderate asthma ( GINA criterion 2 3 ) inadequately control inhaled corticosteroid `` asneeded '' short act betaagonists provide inadequate clinical control ; 3 . Forced expiratory volume one second ( FEV1 ) &gt; 70 % predict normal value demonstrable least 6 hour last short act β2 agonist use 12 hour last long act β2 agonist ( LABA ) use ; 4 . NSS baseline ≥ 3 . Baseline NSS define mean 6 last assessment patient ' diary ( 3 last day randomization ) ; 5 . Positive result skin prick test least one seasonal allergen within last 3 year ; 6 . Patients provide signed write informed consent form ; 7 . Patients able willing complete webbased Patient 's Diary ; 8 . Patients agree maintain consistency surroundings throughout study period ; 9 . Women childbearing potential ( WOCBP ) include perimenopausal woman menstrual period within 1 year negative pregnancy test . Results available Visit 2 negative patient enter study . 10 . WOCBP use effective method birth control throughout study period 4 week study completion ( define method result failure rate le 1 % per year ) : combine ( estrogen progestogen contain ) hormonal contraception associate inhibition ovulation ( oral , intravaginal , transdermal ) progestogenonly hormonal contraception associate inhibition ovulation ( oral , injectable , implantable ) intrauterine device ( IUD ) intrauterine hormonereleasing system ( IUS ) bilateral tubal occlusion vasectomise partner ( provided partner sole sexual partner trial participant vasectomise partner receive medical assessment surgical success ) sexual abstinence In case delay menstrual period ( one month menstruation ) confirmation absence pregnancy strongly recommend . This recommendation also apply WOCBP infrequent irregular menstrual cycle . EXCLUSION CRITERIA 1 . Patients hypersensitivity component study medication ; 2 . Patients nonallergic rhinoconjunctivitis ( e.g . vasomotor , infectious , druginduced ) ; 3 . Presence nasal polyp clinically important nasal anomaly ; 4 . History acute and/or chronic sinusitis within 30 day Visit 2 ; 5 . History eye surgery within 3 month Visit 2 ; 6 . History intranasal surgery within 3 month Visit 2 ; 7 . Immunotherapy within 6 month prior Visit 1 ; 8 . Upper respiratory infection include cold systemic infection within 3 week Visit 2 ; 9 . Patients moderate severe renal impairment take Pgp inhibitor ( e.g . ketoconazole , erythromycin , cyclosporine , ritonavir , diltiazem ) within 7 day prior first dose study medication ; 10 . Patients require daily `` controller '' medication cromolyntype drug leukotriene antagonist ; 11 . Patient require daily `` controller '' medication Inhaled corticosteroid ( ICS ) LABA medium /high dosage define GINA criterion ; 12 . Patients clinically important ( base principal investigator 's judgment ) hepatic impairment ; 13 . Patients severe concomitant disease ( base principal investigator 's judgment ) could interfere treatment response ; 14 . Patients QT syndrome ; 15 . Patients Galactose intolerance , Lapp lactase deficiency glucose galactose malabsorption ; 16 . Pregnant breastfeeding woman ; 17 . Patients mental condition render subject unable understand nature , scope possible consequence study ( base principal investigator 's judgment ) ; 18 . Patients recent history ( within previous 12 month ) drug addiction alcohol abuse base Principal investigator 's judgment ; 19 . Patients participate participate another clinical trial within previous three month ; 20 . Patients unable take relief medication due contraindication intolerance ; 21 . Patients take take follow medication prior randomisation study comply specify washout period : Antihistaminic drug montelukast ( 7 day ) Systemic intranasal corticosteroid ( 4 week ) Delayedrelease corticosteroid ( 3 month ) Ketotifen ( 2 week ) Macrolides antibiotic imidazolic antifungal ( systemic ) ( 7 day ) Anticholinergics ( 7 day ) Drugs antihistamine property ( phenothiazine ) ( 7 day ) Intranasal systemic decongestant ( 3 day ) Lodoxamide ( 7 day ) 22 . Patients operate heavy machinery need drive motor vehicle essential part profession . 23 . Patients plan travel outside study area course study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Bilastine</keyword>
	<keyword>Montelukast</keyword>
	<keyword>total symptom score</keyword>
	<keyword>AQLQ</keyword>
</DOC>